- Home
- BEAM vs MAN Comparison
BEAM vs MAN Comparison
Compare BEAM & MAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- MAN
- Stock Information
- Founded
- BEAM 2017
- MAN 1948
- Country
- BEAM United States
- MAN United States
- Employees
- BEAM N/A
- MAN N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- MAN Professional Services
- Sector
- BEAM Health Care
- MAN Consumer Discretionary
- Exchange
- BEAM Nasdaq
- MAN Nasdaq
- Market Cap
- BEAM 1.7B
- MAN 2.0B
- IPO Year
- BEAM 2020
- MAN 1988
- Fundamental
- Price
- BEAM $17.46
- MAN $41.21
- Analyst Decision
- BEAM Strong Buy
- MAN Hold
- Analyst Count
- BEAM 10
- MAN 5
- Target Price
- BEAM $48.56
- MAN $48.40
- AVG Volume (30 Days)
- BEAM 2.4M
- MAN 885.4K
- Earning Date
- BEAM 08-05-2025
- MAN 07-17-2025
- Dividend Yield
- BEAM N/A
- MAN 5.41%
- EPS Growth
- BEAM N/A
- MAN N/A
- EPS
- BEAM N/A
- MAN N/A
- Revenue
- BEAM $60,272,000.00
- MAN $17,539,500,000.00
- Revenue This Year
- BEAM N/A
- MAN $0.07
- Revenue Next Year
- BEAM $17.18
- MAN $4.05
- P/E Ratio
- BEAM N/A
- MAN N/A
- Revenue Growth
- BEAM N/A
- MAN N/A
- 52 Week Low
- BEAM $13.53
- MAN $37.97
- 52 Week High
- BEAM $35.25
- MAN $75.57
- Technical
- Relative Strength Index (RSI)
- BEAM 39.16
- MAN 48.73
- Support Level
- BEAM $16.65
- MAN $39.12
- Resistance Level
- BEAM $21.40
- MAN $41.78
- Average True Range (ATR)
- BEAM 1.00
- MAN 1.47
- MACD
- BEAM -0.35
- MAN -0.04
- Stochastic Oscillator
- BEAM 13.89
- MAN 40.81
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About MAN ManpowerGroup
ManpowerGroup Inc. is engaged in providing workforce solutions and services. The company provides services that include Recruitment and Assessment, Upskilling, Reskilling, Training and Development, Career Management, Outsourcing, and Workforce Consulting. The reportable segments of the company are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others. The Staffing and Interim segment derives the maximum of the company's revenue. The company derives maximum geographical revenue from the Southern European region.